Literature DB >> 24433591

Quality of life in patients with urticaria and angioedema: assessing burden of disease.

David Weldon1.   

Abstract

Patients with urticaria and/or angioedema have several reasons to have a poor quality of life (QoL). The intensity of pruritus and density of involvement compromise a patient's lifestyle as well as aggravate stressors that affect physical and psychiatric conditions. The burden of illness is significant in not only costs for emergent practitioner visits, but, often, unnecessary laboratory testing and medication expenses. Questionnaires that assess a patient's QoL serve to document benefit to therapies. Objectively documenting changes that are important to patients with urticaria and/or angioedema allows the patients and clinician to accurately assess effectiveness of therapies over long periods of time. Specific surveys that address urticaria (CU-Q2oL and UAS) and angioedema (AE-QoL questionnaire) allow simplified and sensitive assessments for patients with the corresponding condition. Common components of appropriate surveys assess not only intensity of pruritus and wheals but also impact on sleep, interpersonal relationships, and appearances. In considering the most important aspects of several surveys, an example of a survey is provided that focuses on the patient's perception of how their urticaria and/or angioedema impacts their QoL.

Entities:  

Mesh:

Year:  2014        PMID: 24433591     DOI: 10.2500/aap.2014.35.3713

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  14 in total

1.  Disorders for which the allergist-immunologist is particularly well-qualified to treat.

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2015 May-Jun       Impact factor: 2.587

2.  Wheels within wheals: the burden of urticaria and angioedema.

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2015 Mar-Apr       Impact factor: 2.587

3.  Allergic rhinitis: From discernment of symptoms to implementation of new therapeutic modalities.

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2014 Jul-Aug       Impact factor: 2.587

4.  Perspectives on chronic urticaria/angioedema and its treatment.

Authors:  Joseph A Bellanti; Russell A Settiane
Journal:  Allergy Asthma Proc       Date:  2014 Jan-Feb       Impact factor: 2.587

5.  United airway disease.

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2014 Sep-Oct       Impact factor: 2.587

6.  Relievers, controllers, and inhaler technique: A physician-patient challenge.

Authors:  Joseph A Bellanti; Russell A Settipane
Journal:  Allergy Asthma Proc       Date:  2016-09       Impact factor: 2.587

7.  Bilastine: new insight into antihistamine treatment.

Authors:  Erminia Ridolo; Marcello Montagni; Laura Bonzano; Cristoforo Incorvaia; Giorgio Walter Canonica
Journal:  Clin Mol Allergy       Date:  2015-04-15

8.  Involvement of new oxidative stress markers in chronic spontaneous urticaria.

Authors:  Eustachio Nettis; Maria Distaso; Salvatore Saitta; Marco Casciaro; Mariateresa Cristani; Antonina Saija; Angelo Vacca; Sebastiano Gangemi; Paola L Minciullo
Journal:  Postepy Dermatol Alergol       Date:  2017-10-31       Impact factor: 1.837

9.  Gene expression profiles in chronic idiopathic (spontaneous) urticaria.

Authors:  Ojas P Patel; Ralph C Giorno; Donald A Dibbern; Karen Y Andrews; Sonia Durairaj; Stephen C Dreskin
Journal:  Allergy Rhinol (Providence)       Date:  2015-01

10.  Omalizumab substantially improves dermatology-related quality of life in patients with chronic spontaneous urticaria.

Authors:  A Y Finlay; A P Kaplan; L A Beck; E N Antonova; M-M Balp; J Zazzali; S Khalil; M Maurer
Journal:  J Eur Acad Dermatol Venereol       Date:  2017-07-19       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.